Archived AES Symposia 2004
Pregnancy and Epilepsy
Program Length: 1 hrs 40 min
This symposium will provide important practical information to healthcare providers caring for women with epilepsy who are either pregnant or intend to become pregnant. One of the critical issues facing the clinician is how and whether to continue use of antiepileptic agents once a patient becomes pregnant. This issue will be addressed in the discussion of the impact of maternal seizures on the fetus and the use of anti-epileptic drugs (AEDs). The value of established pregnancy registries in distinguishing among risks of different AEDs will also be addressed. Another important concern of the mother and clinician is the eventual developmental and cognitive outcome of the children. Discussion of this topic will provide meaningful information to clinicians to help advise their pregnant patients. The final discussion will provide clinicians with guidance on managing expectations of the patient with epilepsy who is pregnant or intends to become pregnant.
At the conclusion of this activity, participants should be able to:
- Discuss the value of tight control of maternal seizures with AEDs compared with the
risk of congenital malformations associated with AED therapy
- Discuss with patients who have epilepsy the latest information concerning risks of
impaired developmental and cognitive outcomes in their infants
- Identify the various pregnancy registries and how they can help in the overall
management of seizures in pregnant patients
- Describe how current information concerning optimal use of AED therapy, pregnancy
registries, and neurodevelopmental issues can be used to optimize management of
pregnant patients with epilepsy.
Epileptologists, neurologists, neuroscientists, neurosurgeons, pharmacists, nurses, and other healthcare providers who care for patients with epilepsy who are pregnant or intend to become pregnant.
Chair: Mark S. Yerby, M.D.
- Maternal Seizures, Maternal Epilepsy,
and AEDs: The Variables Associated with
Cynthia L. Harden, M.D.
- Development and Cognitive Outcomes of
Infants of Mothers with Epilepsy
Kimford J. Meador, M.D.
- Pregnancy Registries: Their Utility and
Role in Guiding Clinical Decision-Making
W. Allen Hauser, M.D.
This program and its re-purposing on the AES Web site with CME credit is supported by an educational grant from Novartis Pharmaceuticals Corporation.
Co-sponsored by the American Epilepsy Society and the Center for Advanced Medical Education, Inc.
Dr Yerby has disclosed that he has served as a consultant for GlaxoSmithKline and has served on the speakers bureaus for Abbott Laboratories Inc., Novartis Pharmaceuticals Corporation, and Xcel Pharmaceuticals, Inc.
Dr Yerby has disclosed that he will not be discussing the unlabeled/unapproved use of any product.
Dr Harden has disclosed that she has received grant/research support for AstraZeneca, GlaxoSmithKline, IVAX Pharmaceuticals, Inc, and Pfizer Inc. She has served as consultant for UCB Pharma, Inc., and has received honoraria from GlaxoSmithKline, Novartis Pharmaceuticals Corporation, Ortho-McNeil Pharmaceutical, Inc., and UCB Pharma.
Dr Harden has disclosed that she will not be discussing the unlabeled/unapproved use of any product.
Dr. Meador has disclosed that he has recieved grant/research support from GlaxoSmithKline; Ortho-McNeil Pharmaceutical, Inc.; Pfizer Inc; SAM Technology, Inc; Shire US Inc; and UCB Pharma, Inc
He has also served as a consultant: Abbott Laboratories; GlaxoSmithKline; Elan Corporation, plc; Lexicor Health System, Inc; NeuroPace, Inc; Novartis Pharmaceuticals Corporation; Ortho-McNeil Pharmaceutical, Inc; Pfizer Inc; Shire US Inc; and UCB Pharma, Inc and has received honoraria from GlaxoSmithKline; Ortho-McNeil Pharmaceutical, Inc; Pfizer Inc; Shire US Inc; and UCB Pharma, Inc
Dr Meador has disclosed that he will not be discussing the unlabeled/unapproved use of any products.
Dr Hauser has disclosed that he has no significant relationships with commercial supporters.
Dr Hauser has disclosed that he will not be discussing the unlabeled/unapproved use of any products.